BRAF and neoplasm: Because the number of samples analyzed in the present study was limited, and the tumor cell content of some of the archival samples was scant, we were unable to determine the full diagnostic utility of LCPCR detection of the BRAF activating point mutation on indeterminate thyroid aspirates.